rpn-13 Antibody

What is Rpn13 and why is it important in proteasome research?

Rpn13 is one of several ubiquitin receptors in the 26S proteasome responsible for recruiting polyubiquitinated substrates for degradation. It serves dual functions: binding ubiquitinated proteins targeted for degradation and recruiting the deubiquitinase Uch37 to the proteasome while strongly stimulating its enzymatic activity . Rpn13 has gained significant research interest because it's overexpressed in various cancers including multiple myeloma, ovarian, cervical, pancreatic, and colorectal cancers . Studies have shown that its depletion using genetic methods leads to reduced cancer cell viability, making it a potential therapeutic target . Rpn13 binds to the Rpn2 component of the proteasome, which serves as its docking site .

What types of Rpn13 antibodies are available for research applications?

Researchers typically have access to several types of Rpn13 antibodies designed for different applications:

• Monoclonal antibodies: Produced from single B-cell clones, these target specific epitopes of Rpn13 and offer high specificity and reproducibility between experiments.

• Polyclonal antibodies: Generated in animals immunized with Rpn13 peptides or recombinant proteins, these recognize multiple epitopes and are useful for applications requiring high sensitivity.

• Domain-specific antibodies:

  • Pru domain antibodies: Target the N-terminal pleckstrin-like receptor for ubiquitin domain responsible for ubiquitin binding

  • DEUBAD domain antibodies: Recognize the C-terminal DEUBiquitinase ADaptor domain that interacts with Uch37

• Tagged antibodies: For specialized applications such as immunofluorescence or flow cytometry.

When selecting an antibody, researchers should consider the specific domain of Rpn13 they're interested in studying, as evidence shows that different domains mediate distinct functions .

What are the established applications for Rpn13 antibodies in proteasome research?

Rpn13 antibodies have diverse research applications across proteasome biology and cancer research:

• Western blotting: For detecting and quantifying Rpn13 protein levels in cell or tissue lysates (approximately 43 kDa band) .

• Immunoprecipitation: For isolating Rpn13 complexes to study protein-protein interactions, such as with Uch37 or proteasome components like Rpn2 .

• Immunofluorescence: For visualizing subcellular localization of Rpn13 and its potential redistribution under different conditions or treatments.

• Co-localization studies: For examining the spatial relationship between Rpn13 and other proteasome components or ubiquitinated substrates.

• Drug target validation: For investigating how potential inhibitors like RA190, CLEFMA, or EF24 interact with or affect Rpn13 .

• Proteasome complex isolation: Anti-β5 antibodies can immunoprecipitate the proteasome, allowing detection of co-immunoprecipitated Rpn13 to study its association with the proteasome complex .

• Proximity ligation assays: For detecting in situ protein-protein interactions involving Rpn13 .

How should I optimize Western blot protocols for detecting Rpn13?

Optimizing Western blot protocols for Rpn13 detection requires attention to several key factors:

• Sample preparation:

  • Include protease inhibitors in lysis buffers to prevent degradation

  • For studying intact proteasome complexes, use gentle non-denaturing buffers

  • When examining Rpn13-drug interactions, ensure the lysis buffer doesn't interfere with binding

• Protein separation:

  • Use 10-12% SDS-PAGE gels for optimal separation, as Rpn13 has a molecular weight of approximately 43 kDa

  • Load 20-50 μg of total protein per lane for adequate detection

• Transfer and blocking:

  • PVDF membranes may provide better results than nitrocellulose

  • Block with 5% non-fat dry milk in TBST to minimize background

• Antibody incubation:

  • Primary antibody dilutions typically range from 1:500 to 1:2000

  • Incubate primary antibody overnight at 4°C for best results

• Controls:

  • Include positive controls (cells known to express Rpn13, such as HeLa or MM1.R cells)

  • Consider including Rpn13 knockdown samples as negative controls

  • Use housekeeping proteins (e.g., GAPDH, β-actin) as loading controls

Studies have shown that Western blot is effective for detecting changes in Rpn13 levels, as demonstrated in experiments examining Rpn13 overexpression, where the level of FLAG-Rpn13 in cells was 8-10 fold higher than native Rpn13 .

What are effective methods for studying Rpn13 interactions with the proteasome?

Studying Rpn13 interactions with the proteasome requires carefully designed approaches:

• Immunoprecipitation strategies:

  • Direct IP: Using anti-Rpn13 antibodies to pull down Rpn13 and associated proteins

  • Reverse IP: Using antibodies against other proteasome components (e.g., anti-β5 antibody) to pull down the entire proteasome complex and detect co-immunoprecipitated Rpn13

  • For studying the Rpn13-Rpn2 interaction specifically, use antibodies against either protein

• Lysis and buffer conditions:

  • Use gentle, non-denaturing buffers (e.g., 50 mM Tris-HCl, 150 mM NaCl, 0.5-1% NP-40)

  • Include protease inhibitors to prevent degradation during processing

  • For detecting intact complexes, avoid harsh detergents that disrupt protein interactions

• Controls and validation:

  • Include IgG controls to assess non-specific binding

  • Compare bound fractions with input samples

  • For drug studies, include both treated and untreated controls

• Detection methods:

  • Western blot with specific antibodies against expected interaction partners

  • Mass spectrometry for unbiased identification of all interacting proteins

Research has demonstrated that Rpn13 can be efficiently co-immunoprecipitated with proteasomes using anti-β5 antibodies, allowing assessment of whether compounds like biotin-RA190 affect Rpn13 association with the proteasome .

How can I use Rpn13 antibodies to study drug interactions with the proteasome?

Rpn13 antibodies provide valuable tools for investigating how compounds interact with the proteasome:

• Direct binding assays:

  • DARTS (Drug Affinity Responsive Target Stability): This technique examines if compound binding to Rpn13 confers protection against proteolysis catalyzed by proteases like thermolysin

  • Pull-down assays: Using biotinylated compounds (e.g., biotin-CLEFMA, biotin-RA190) to capture Rpn13, followed by detection with Rpn13 antibodies

  • Competition assays: Pre-incubating with non-biotinylated compounds before adding biotinylated analogs to confirm specific binding

• Structural studies:

  • 2D-gel electrophoresis combined with Western blotting to identify specific binding sites

  • Mass spectrometry analysis of drug-protein complexes to map interaction sites

• Functional assays:

  • Examining how compounds affect Rpn13's association with the proteasome using co-immunoprecipitation with anti-β5 antibodies

  • Monitoring changes in ubiquitinated protein accumulation after drug treatment

  • Evaluating effects on Rpn13-Uch37 interactions

• Cellular studies:

  • Comparing drug sensitivity in cells with different Rpn13 expression levels

  • Examining how drugs affect Rpn13 localization using immunofluorescence

Research has shown contradictory results regarding RA190's interaction with Rpn13. Some studies found no evidence that biotin-RA190 alkylates Rpn13 in melanoma or multiple myeloma cells, while others reported binding . This highlights the importance of using multiple complementary approaches when studying drug-target interactions.

What controls should be included when performing experiments with Rpn13 antibodies?

Including appropriate controls is essential for experiments with Rpn13 antibodies:

• Positive controls:

  • Cell lines known to express Rpn13 (e.g., MM1.R, HeLa, SK-MEL-5)

  • Recombinant Rpn13 protein

  • Cells transfected with Rpn13 expression constructs

• Negative controls:

  • Rpn13 knockdown cells (siRNA or shRNA treated)

  • Primary antibody omission controls (for IF/IHC)

  • Isotype controls (matching antibody class but non-specific)

• Specificity controls:

  • Peptide competition/blocking (pre-incubate antibody with immunizing peptide)

  • Multiple antibodies targeting different Rpn13 epitopes

• Experiment-specific controls:

  • For drug studies (e.g., RA190):

    • Vehicle-treated controls

    • Treatment with inactive analogs

    • Dose-response samples

• Technical controls:

  • Loading controls for Western blots (housekeeping proteins)

  • Input samples for immunoprecipitation experiments

A practical example from the literature demonstrates the value of comprehensive controls: In studies examining whether Rpn13 is the target of RA190, researchers used multiple approaches including overexpression of wild-type Rpn13 and Rpn13C88A mutant, and knockdown of native Rpn13. These controls revealed that changing Rpn13 levels did not affect cellular sensitivity to RA190, challenging the hypothesis about RA190's mechanism of action .

How can I validate the specificity of Rpn13 antibodies?

Thorough validation of Rpn13 antibodies is crucial for ensuring experimental reliability:

• Genetic validation approaches:

  • siRNA/shRNA knockdown: Compare antibody signal in control vs. Rpn13-depleted samples

  • Overexpression: Test antibody detection in cells with ectopic expression of Rpn13

• Biochemical validation:

  • Western blot: Confirm detection of a band at the expected molecular weight (~43 kDa for full-length human Rpn13)

  • Recombinant protein detection: Test antibody against purified recombinant Rpn13 protein

  • Multiple antibody comparison: Use antibodies from different sources targeting different epitopes

• Application-specific validation:

  • For IP: Verify pull-down of known Rpn13 interaction partners (e.g., Uch37, Rpn2)

  • For co-localization experiments: Confirm detection of Rpn13 at expected subcellular locations

• Drug binding site studies:

  • When studying potential Rpn13-targeting compounds, use multiple complementary approaches

  • Consider how antibody binding might be affected by drug binding to the same region

Studies investigating Rpn13 as a target for compounds like CLEFMA used complementary approaches including DARTS assays, 2D-gel electrophoresis, and co-localization experiments to validate antibody specificity and confirm target engagement .

What are common pitfalls when working with Rpn13 antibodies and how can they be avoided?

Researchers working with Rpn13 antibodies may encounter several common pitfalls:

• Cross-reactivity issues:

  • Problem: Antibodies may detect proteins with similar epitopes to Rpn13

  • Solution: Validate antibody specificity using Rpn13 knockdown samples as negative controls

  • Recommendation: Use monoclonal antibodies for applications requiring high specificity

• Inconsistent detection of proteasome-bound versus free Rpn13:

  • Problem: Different pools of Rpn13 may be detected differently depending on antibody epitope accessibility

  • Solution: Use antibodies targeting different Rpn13 domains (Pru vs. DEUBAD) and compare results

  • Recommendation: For comprehensive analysis, employ multiple antibodies recognizing different epitopes

• Interference with drug binding sites:

  • Problem: Antibodies targeting certain Rpn13 regions may interfere with or be affected by drug binding (e.g., RA190)

  • Solution: For drug studies, carefully select antibodies targeting epitopes distant from the drug binding site

  • Recommendation: Perform control experiments to ensure the drug doesn't affect antibody binding

• Buffer compatibility issues:

  • Problem: Some lysis or immunoprecipitation buffers may disrupt Rpn13 interactions

  • Solution: Use gentle non-denaturing buffers for studying protein-protein interactions

  • Recommendation: Optimize buffer composition for each specific application

• Contradictory results interpretation:

  • Problem: Different experimental approaches may yield conflicting results

  • Solution: Use multiple methods and antibodies to build a comprehensive picture

  • Example: Studies of RA190 found contradictory results about its interaction with Rpn13

By anticipating these potential pitfalls and implementing the suggested solutions, researchers can significantly improve the reliability and reproducibility of experiments using Rpn13 antibodies.

How should I interpret contradictory results with Rpn13 antibodies in drug studies?

Contradictory results from Rpn13 antibody studies in drug research require systematic evaluation:

When faced with contradictory results, the most scientifically sound approach is to acknowledge the discrepancies, thoroughly analyze methodological differences, and design experiments that can definitively resolve the contradictions.

What can Rpn13 antibody studies tell us about proteasome inhibitor mechanisms?

Rpn13 antibody-based studies provide valuable insights into proteasome inhibitor mechanisms through multiple approaches:

• Differentiating inhibitor mechanisms:

  • Traditional proteasome inhibitors (e.g., bortezomib) target the 20S catalytic core

  • Newer approaches target regulatory particles, including Rpn13

  • Rpn13 antibodies can help determine whether compounds act through:

    • Blocking substrate recruitment

    • Preventing deubiquitinating enzyme activation

    • Disrupting Rpn13's interaction with Rpn2 or the proteasome

• Comparing downstream effects:

  • Conventional proteasome inhibitors targeting the 20S core particle invariably induce autophagy

  • Some putative Rpn13-targeting compounds show different effects:

    • CLEFMA and EF24 had no apparent effect on autophagy markers LC3B and beclin

    • RA190 triggered autophagy in multiple myeloma cells

  • These differences highlight distinct mechanisms of action that can be detected using Rpn13 antibodies

• Evaluating drug binding:

  • Direct binding assays using biotinylated compounds and Rpn13 antibodies can confirm target engagement

  • Co-localization experiments can show whether drugs and Rpn13 interact in cellular contexts

  • Competition assays can determine binding specificity and identify binding sites

• Assessing proteasome complex integrity:

  • Rpn13 antibodies can detect whether inhibitors disrupt Rpn13's association with the proteasome

  • Studies found that biotin-RA190 had no effect on the amount of Rpn13 that co-immunoprecipitates with the proteasome

These approaches allow researchers to develop a more nuanced understanding of how different proteasome inhibitors function, potentially leading to more effective and selective therapeutic strategies.

How can Rpn13 antibodies help differentiate between free and proteasome-bound Rpn13?

Distinguishing between free and proteasome-bound Rpn13 populations is crucial for understanding proteasome biology and drug mechanisms:

• Co-immunoprecipitation approaches:

  • Use anti-β5 antibodies to immunoprecipitate intact proteasomes

  • Detect co-immunoprecipitated Rpn13 using Rpn13-specific antibodies

  • Compare with total Rpn13 levels in whole cell lysates

  • This approach can reveal what proportion of cellular Rpn13 is proteasome-associated

• Fractionation techniques:

  • Use gradient centrifugation to separate proteasome complexes from free proteins

  • Probe fractions with Rpn13 antibodies to identify distribution patterns

  • Changes in distribution patterns can indicate drug effects on Rpn13-proteasome association

• Proximity-based detection:

  • Proximity ligation assays using antibodies against Rpn13 and core proteasome components

  • This approach visualizes interactions in intact cells with spatial resolution

• Structure-based investigations:

  • Structural studies have revealed that Rpn13 binds to Rpn2 via specific interfaces

  • In the bound state, a proline-rich C-terminal Rpn2 extension stretches across a narrow canyon of the ubiquitin-binding Rpn13 Pru domain

  • This structural arrangement may affect antibody accessibility to certain epitopes

• Drug interaction studies:

  • Research has shown that Rpn13 exists both within and outside of proteasomes

  • The Rpn13 population not associated with proteasomes may be more susceptible to certain inhibitors

  • Understanding which pool is targeted can be critical for interpreting drug effects

By employing these approaches, researchers can gain insights into the dynamic distribution of Rpn13 and how this distribution might change under different conditions or in response to therapeutic interventions.

How can Rpn13 antibodies be used to study cancer biology?

Rpn13 antibodies offer powerful tools for investigating cancer biology through multiple approaches:

• Expression analysis in cancer tissues:

  • Immunohistochemistry using validated Rpn13 antibodies can assess expression across cancer types

  • Western blot quantification can compare Rpn13 levels in tumor versus normal tissues

  • Research has shown Rpn13 overexpression in multiple cancer types, including multiple myeloma, ovarian, cervical, pancreatic, and colorectal cancers

• Functional studies:

  • Combine Rpn13 antibodies with markers of cellular processes to understand mechanism

  • Evidence indicates that knockdown of Rpn13 inhibits cellular proliferation and migration while inducing apoptosis in cancer cell lines

  • Rpn13 and Uch37 are essential for robust cell cycle progression in HeLa cells

• Drug development applications:

  • Validate novel Rpn13-targeting compounds using antibody-based detection

  • Monitor changes in Rpn13-dependent processes following treatment

  • Compounds like RA190 have shown anti-cancer activities, though their exact mechanisms remain debated

  • The peptoid KDT-11 has been discovered as a selective and reversible ligand for Rpn13 with synergistic effects with bortezomib

• Resistance mechanism investigations:

  • Compare Rpn13 expression and localization in drug-sensitive versus resistant cancer cells

  • Study alterations in Rpn13-proteasome association in resistant cells

  • Induction of compensatory autophagy by proteasome inhibitors is one mechanism of bortezomib resistance

• Biomarker development:

  • Standardized Rpn13 antibody assays can establish expression thresholds for predicting treatment response

  • Track changes in Rpn13 levels during disease progression or treatment

This multifaceted approach using Rpn13 antibodies can significantly advance our understanding of cancer biology and potentially lead to improved therapeutic strategies targeting proteasome function in cancer.

How can Rpn13 antibodies help investigate the relationship between the proteasome and autophagy?

Rpn13 antibodies provide valuable tools for investigating the complex interplay between the ubiquitin-proteasome system and autophagy:

• Monitoring compensatory mechanisms:

  • Use Rpn13 antibodies alongside autophagy markers (LC3B, p62, Beclin-1) to track parallel changes

  • Research has revealed important differences between inhibitor classes:

    • Conventional proteasome inhibitors targeting 20S core particle invariably induce autophagy

    • CLEFMA and EF24 (compounds similar to RA190) had no apparent effect on autophagy markers LC3B and beclin in proteasome reporter cell lines

    • RA190 has been found to trigger autophagy in multiple myeloma cells

• Understanding differential responses:

  • This observation is significant since induction of compensatory autophagy by proteasome inhibitors has been regarded as one reason for emergence of bortezomib resistance

  • Autophagy may act as a backup system for the ubiquitin-proteasome system

  • Compounds that don't induce compensatory autophagy might potentially overcome certain resistance mechanisms

• Mechanistic investigations:

  • Co-immunoprecipitation with Rpn13 antibodies can identify proteins involved in cross-talk between degradation systems

  • Immunofluorescence studies can reveal spatial relationships between proteasomes and autophagic structures

  • Quantitative analysis can determine the kinetics of pathway switching following different interventions

• Therapeutic implications:

  • Understanding how Rpn13 inhibition affects autophagy could lead to more effective combination strategies

  • Targeting both degradation pathways simultaneously might prevent compensatory mechanisms

  • Rpn13 antibodies can help monitor pathway status during treatment optimization

The ability to simultaneously monitor proteasome function (via Rpn13) and autophagy provides a comprehensive view of cellular degradation systems and their adaptations to therapeutic interventions or stress conditions.

What emerging techniques combine Rpn13 antibodies with other research tools?

Advanced proteasome research increasingly integrates Rpn13 antibodies with cutting-edge technologies:

• Proximity-based labeling techniques:

  • BioID or TurboID approaches can identify proteins in close proximity to Rpn13

  • Verify expression and localization using Rpn13 antibodies

  • This can reveal novel interaction partners and spatial relationships within the cellular environment

• CRISPR-based approaches:

  • Generate Rpn13 knockout or knockdown models for antibody validation

  • Create tagged endogenous Rpn13 for comparing with antibody detection

  • Study the consequences of Rpn13 disruption on proteasome function

• Advanced microscopy:

  • Super-resolution microscopy with Rpn13 antibodies can resolve subproteasomal structures

  • Live-cell imaging approaches track proteasome dynamics in real-time

  • Correlate structure with function by combining with fluorescent substrates

• Chemical proteomics:

  • Combine drug pull-downs with antibody validation

  • Use biotinylated compounds like biotin-CLEFMA and biotin-EF24 to capture Rpn13

  • In 2D-gel electrophoresis studies, coomassie-stained gels can be compared with transfer membranes probed with HRP-streptavidin to identify binding partners

• Drug development tools:

  • DARTS (Drug Affinity Responsive Target Stability) technique examines if compound binding to Rpn13 confers protection against proteolysis

  • Competition assays using unlabeled compounds can verify binding specificity

  • These approaches have identified several potential Rpn13-targeting molecules, including CLEFMA, EF24, and RA190

• Structure-function studies:

  • Recent structural work has solved the structure of hRpn13 with a segment of hRpn2 that serves as its proteasome docking site

  • A proline-rich C-terminal hRpn2 extension stretches across a narrow canyon of the ubiquitin-binding hRpn13 Pru domain, blocking an RA190-binding surface

  • These structural insights combined with antibody-based functional studies are enhancing our understanding of proteasome assembly and inhibition

These innovative combinations provide unprecedented insights into proteasome biology and may lead to more effective therapeutic approaches targeting this essential cellular machinery.